FindTrial
Sign In

Identification of Genetic Changes in Indian Lung Cancer Patients

Identification of Circulating Tumor DNA Mutations in Indian Lung Cancer Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/12/022284
Enrollment
50
Registered
2019-12-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C34- Malignant neoplasm of bronchus andlung

Interventions

None listed

Sponsors

DST INSPIRE Fellowship
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with lung cancer Age less than 75 years and more than 18 years Patients who are willing to give informed consent

Exclusion criteria

Exclusion criteria: HIV positive lung cancer patients Patients with seriously ill conditions and major co-morbidities

Design outcomes

Primary

MeasureTime frame
Detection of EGFR T790M mutation in ctDNA using liquid biopsy (CastPCR technology) in lung cancer patients.Timepoint: 3 years—

Secondary

MeasureTime frame
Demographic characteristics, clinical presentations, Histopathology reports, diagnostic results, Clinical response and survival in different sequence of chemotherapy /EGFR Tyrosine Kinase Inhibitors in lung cancer patients. Timepoint: 3 years—

Countries

India

Contacts

Public ContactDr Mahadev Rao

Manipal College of Pharmaceutical Sciences

mahadev.rao@manipal.edu8105706060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026